Pharma major Lupin Ltd. announced that its subsidiary Lupin Pharmaceuticals Inc. had received final approval for its Irbesartan Tablets, 75 mg, 150 mg and 300 mg from the US FDA to market a generic version of Sanofi Aventis US, LLC's Avapro tablets, 75 mg, 150 mg and 300 mg strengths.
Irbesartan is an angiotensin II receptor antagonist and is indicated for the treatment of Hypertension and Nephropathy in Type 2 diabetic patients.
As per IMS MAT data, Avapro tablets had annual sales of around $400.70 million as at the end of June 2012.
A the NSE, Lupin shares are currently trading at Rs.564.85, up 1.67 percent from the previous close.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.